GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TetraLogic Pharmaceuticals Corp (OTCPK:TLOG) » Definitions » Gross Profit

TetraLogic Pharmaceuticals (TetraLogic Pharmaceuticals) Gross Profit : $0.00 Mil (TTM As of Sep. 2016)


View and export this data going back to 2013. Start your Free Trial

What is TetraLogic Pharmaceuticals Gross Profit?

TetraLogic Pharmaceuticals's gross profit for the three months ended in Sep. 2016 was $0.00 Mil. TetraLogic Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Sep. 2016 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. TetraLogic Pharmaceuticals's gross profit for the three months ended in Sep. 2016 was $0.00 Mil. TetraLogic Pharmaceuticals's Revenue for the three months ended in Sep. 2016 was $0.00 Mil. Therefore, TetraLogic Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2016 was N/A%.

TetraLogic Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Sep. 2016 => No sustainable competitive advantage


TetraLogic Pharmaceuticals Gross Profit Historical Data

The historical data trend for TetraLogic Pharmaceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TetraLogic Pharmaceuticals Gross Profit Chart

TetraLogic Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15
Gross Profit
- - - - -

TetraLogic Pharmaceuticals Quarterly Data
Dec11 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of TetraLogic Pharmaceuticals's Gross Profit

For the Biotechnology subindustry, TetraLogic Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TetraLogic Pharmaceuticals's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TetraLogic Pharmaceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where TetraLogic Pharmaceuticals's Gross Profit falls into.



TetraLogic Pharmaceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

TetraLogic Pharmaceuticals's Gross Profit for the fiscal year that ended in Dec. 2015 is calculated as

Gross Profit (A: Dec. 2015 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

TetraLogic Pharmaceuticals's Gross Profit for the quarter that ended in Sep. 2016 is calculated as

Gross Profit (Q: Sep. 2016 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

TetraLogic Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2016 is calculated as

Gross Margin % (Q: Sep. 2016 )=Gross Profit (Q: Sep. 2016 ) / Revenue (Q: Sep. 2016 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


TetraLogic Pharmaceuticals  (OTCPK:TLOG) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

TetraLogic Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Sep. 2016 => No sustainable competitive advantage


TetraLogic Pharmaceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of TetraLogic Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


TetraLogic Pharmaceuticals (TetraLogic Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
343 Phoenixville Pike, Malvern, PA, USA, 19355
TetraLogic Pharmaceuticals Corp is a biopharmaceutical company. The company is engaged in developing novel small molecule therapeutics in oncology.
Executives
Hudson Bay Capital Management Lp other: See Remarks 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Lazard Asset Management Llc other: See Remarks 30 ROCKEFELLER PLZ, 56TH FL., NEW YORK NY 10112
Nomura Holdings Inc other: See Remarks 1-13-1 NIHONBASHI, CHUO-KU, TOKYO M0 103-8645
Whitebox Multi-strategy Partners Lp other: See Remarks 3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Pandora Select Partners, L.p. other: See Remarks 3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Whitebox General Partner Llc other: See Remarks 3033 EXCELSIOR BLVD., SUITE 300, MINNEAPOLIS MN 55416
Highbridge Capital Management Llc other: See Remarks 277 PARK AVE, 23RD FLOOR, NEW YORK NY 10172
Sander Gerber other: See Remarks C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Whitebox Concentrated Convertible Arbitrage Partners, L.p. other: See Remarks 3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Whitebox Advisors Llc other: See Remarks 3033 EXCELSIOR BLVD., SUITE 500, MINNEAPOLIS MN 55416
Patrick Hutchison officer: CFO & Treasurer C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803
Clarus Ventures Ii, Llc 10 percent owner 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Clarus Lifesciences Ii, L.p. 10 percent owner 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Clarus Ventures Ii Gp, L.p. 10 percent owner 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Nicholas Simon 10 percent owner 101 MAIN STREET SUITE 1210, CAMBRIDGE MA 02142

TetraLogic Pharmaceuticals (TetraLogic Pharmaceuticals) Headlines

No Headlines